SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Net Issuance of Debt
SCI Pharmtech Inc
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Net Issuance of Debt
-NT$61.7m
|
CAGR 3-Years
-226%
|
CAGR 5-Years
-100%
|
CAGR 10-Years
-1%
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Net Issuance of Debt
-NT$120.6m
|
CAGR 3-Years
40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-15%
|
|
![]() |
Formosa Laboratories Inc
TWSE:4746
|
Net Issuance of Debt
-NT$261.4m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
ScinoPharm Taiwan Ltd
TWSE:1789
|
Net Issuance of Debt
-NT$10.3m
|
CAGR 3-Years
20%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
![]() |
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Net Issuance of Debt
NT$1.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-3%
|
|
![]() |
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Net Issuance of Debt
-NT$773.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-52%
|
CAGR 10-Years
-25%
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Net Issuance of Debt?
Net Issuance of Debt
-61.7m
TWD
Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's Net Issuance of Debt amounts to -61.7m TWD.
What is SCI Pharmtech Inc's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 10Y
-1%
The average annual Net Issuance of Debt growth rates for SCI Pharmtech Inc have been -226% over the past three years , -100% over the past five years , and -1% over the past ten years .